Introduction: IgA nephropathy (IgAN) is one of the most common forms glomerulonephritis worldwide. It leads to end-stage renal disease (ESRD) in many patients. At time diagnosis, risk stratification paramount importance planning proper management individual cases. Several studies have been conducted determine utility various demographic, clinical, laboratory, and pathological features on biopsy...

CONTEXT AND OBJECTIVE Epidemiological data provide useful information for clinical practice and investigations. This study aimed to determine glomerular disease frequencies in a region of Colombia and it represents the basis for future studies. DESIGN AND SETTING Single-center retrospective analysis at the University of Antioquia, Colombia. METHODS All native renal biopsies (July 1998 to De...

S U M M A R Y 1. Platelet survival was measured in patients with acute proliferative glomerulonephritis or chronic renal failure and also in control subjects. 2. Platelet survival is markedly reduced in acute proliferative glomerulonephritis as compared with control subjects; it was slightly reduced in patients in chronic renal failure due to interstitial renal disease and maintained on dialysis.

BACKGROUND IgA glomerulonephritis (IgAGN) has a highly variable prognosis with 15-40% of patients progressing to end-stage renal disease. Hypertension, proteinuria and renal insufficiency are risk factors associated with poor prognosis. The role of insulin resistance is unclear in IgAGN. METHODS From a retrospective cohort of IgAGN patients, a total of 174 patients (104 males) were invited fo...

Primary IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide [1,2]. Although IgAN was considered a benign condition for many years, we now know that many cases eventually progress to end-stage renal failure. According to recent reviews, the actuarial renal survival at 10 years is 80–85% in most studies. Moreover, 30–40% of affected individuals develop end-stage...

OBJECTIVES To evaluate the role of serum IgG, IgM and IgA anti-dsDNA antibody isotypes in the diagnosis of systemic lupus erythematosus (SLE), and their association with clinical features and disease activity, in a large cohort of SLE patients. METHODS Sera of 200 SLE patients (mean age 34±10.3 years; 26 male and 174 female; median duration of disease 115 months, range 7-378), and of 206 cont...

Two patients with ankylosing spondylitis were found to have IgA nephropathy and leucocytoclastic cutaneous vasculitis. Immunofluorescence showed perivascular deposition of IgA in the skin of one patient and in the mesangium of both patients. Such an association has been reported only once before. This supports the concept of abnormal IgA immune stimulation in the pathogenesis of ankylosing spon...

BACKGROUND There are few reports of glomerulonephritis (GN) with crescents and a rapidly progressive course that lead to a diagnosis of a previously unsuspected B-cell dyscrasia. CASE PRESENTATION We report a case of rapidly progressive GN: the patient showed no evidence of etiology at the time of biopsy and was diagnosed as IgA multiple myeloma (MM) during investigation based on a renal biop...

BACKGROUND IgA glomerulonephritis (IgAGN) composes a variable prognosis with 15-40% of the patients eventually progressing to end-stage renal failure. Known risk factors for progressive course of IgAGN include hypertension, proteinuria and renal insufficiency. Although markers of inflammation such as serum or urinary interleukin-6 (IL-6) and serum albumin have predicted progression in some stud...

Adalimumab (Humira) is a tumour necrosis factor α (TNF α ) inhibitor that is approved for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, and juvenile idiopathic arthritis (Sullivan and Preda (2009), Klinkhoff (2004), and Medicare Australia). Use of TNF α inhibitors is associated with the induction of autoimmunity (systemic lupus e...